COVID-19 cases in India: Official sources said on Wednesday that the Serum Institute of India has written to the Union health ministry seeking inclusion of its Covid vaccine Covax as admixed booster dose for adults in the CoWIN portal. He said the letter was written by Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII).
The Drug Controller General of India (DCGI) has approved the market authorization for Covovax on January 16 as an asymptomatic booster dose for adults who have been given two doses of Covishield or Covaxin.
The DCGI’s approval was based on the recommendations of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation. DCGI approved Covax for restricted use in emergency situations in adults on December 28, 2021, in 12-17 age group on March 9, 2022 and in children aged seven to 11 years on June 28 last year, subject to certain conditions Gave it
Covax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization and was granted an emergency-use list by the World Health Organization (WHO) on December 17, 2021. In August 2020, US-based vaccine manufacturer Novavax Inc. had previously announced a license agreement with SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-middle-income countries.
(With PTI inputs)